Phase 2 trial shows oveporexton improves sleep and wakefulness in narcolepsy patients, suggesting potential benefits.
The orexin receptor 2‐selective agonist oveporexton improved sleep‐ and wakefulness‐related measures in a dose‐dependent fashion relative to placebo in adults with narcolepsy type 1, a Phase 2 study has found. Most adverse events associated with oveporexton were mild to moderate, with no reports of suicidality.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: